Overview
A long-approved hormone with well-defined indications and one of the most thoroughly debunked claims in diet history. The legitimate uses are real; the weight-loss protocol is not.
FDA ApprovedFDA-approved for hypogonadotropic hypogonadism, prepubertal cryptorchidism, and ovulation induction. FDA prohibited OTC hCG weight-loss products in 2011.
| Regulatory status | FDA-approved for hypogonadotropic hypogonadism, prepubertal cryptorchidism, and ovulation induction. FDA prohibited OTC hCG weight-loss products in 2011. |
|---|---|
| Drug class | Glycoprotein hormone with an LH-like beta subunit — technically a glycoprotein rather than a simple peptide |
| Route | Intramuscular or subcutaneous |
| Half-life | ~24–36 hours |
| Evidence rating |
5/5 Very strong
Evidence rating 5 out of 5: Very strong
Multiple phase 3 randomized trials plus regulatory approval in a major market. |
| Studied in | Decades of trials in fertility, hypogonadism and cryptorchidism; multiple randomized trials specifically testing and refuting the hCG diet. |
How it works
Binds and activates the LH receptor, stimulating Leydig cell testosterone production in men and triggering ovulation in women. Its long half-life relative to LH makes it useful clinically.
Evidence base
Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.
- A useful example of strong evidence both for legitimate uses and against a popular misuse.
Benefits & potential uses
Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.
-
Restores testicular testosterone production Strong evidence
Established efficacy in hypogonadotropic hypogonadism and in preserving testicular function during exogenous testosterone therapy.
-
Preserves fertility on TRT Strong evidence
Maintains intratesticular testosterone and spermatogenesis where testosterone alone would suppress both.
-
Ovulation induction Strong evidence
Standard trigger in assisted reproduction protocols.
-
Cryptorchidism treatment Strong evidence
Approved use in prepubertal boys with undescended testes.
Risks, cons & cautions
Bars indicate seriousness: three = serious or common, two = moderate, one = minor.
-
The hCG diet does not work Serious
Randomized trials repeatedly found no weight loss or appetite benefit beyond the accompanying 500-calorie diet — which is itself the actual and dangerous intervention.
-
Ovarian hyperstimulation syndrome Serious
A potentially life-threatening complication of ovulation induction requiring specialist monitoring.
-
Estradiol elevation and gynecomastia in men Moderate evidence
Increased testosterone production raises aromatisation; gynecomastia is a common consequence.
-
Thromboembolism risk Serious
Reported particularly in the context of ovarian hyperstimulation.
-
Multiple pregnancy Moderate evidence
A recognised consequence of ovulation induction.
-
Precocious puberty in boys Moderate evidence
Risk when used in prepubertal patients without endocrinology supervision.
Who should avoid it
- Hormone-sensitive cancers including prostate cancer
- Precocious puberty
- Unexplained uterine bleeding
- Weight-loss use of any kind
If used under medical supervision, monitor
- Testosterone and estradiol in men
- Ultrasound and estradiol during ovulation induction
- Hematocrit
Interactions
Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.
- Exogenous testosterone — suppresses the axis hCG is being used to preserve; timing and dosing matter
- Aromatase inhibitors — often co-prescribed to control the estradiol rise from increased testosterone production
- Gonadotropin preparations — additive ovarian hyperstimulation risk
Regulatory & legal status
Prescription drug. OTC and homeopathic hCG weight-loss products are unlawful in the US.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on Human Chorionic Gonadotropin (hCG)
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
- DailyMed — official FDA prescribing information
Related peptides in Hormonal & Reproductive
Terms used on this page
- Testosterone
- Testosterone is the principal androgen, a 19-carbon steroid made mainly by testicular Leydig cells and converted peripherally to dihydrotestosterone by 5-alpha-reductase and to estradiol by aromatase.
- Terminal Half-Life
- Terminal half-life is the time taken for drug concentration to fall by half during the final, slowest phase of elimination, and it sets the dosing interval.
- Primary vs Secondary Hypogonadism
- Primary hypogonadism is gonadal failure with raised gonadotropins, while secondary hypogonadism is a low sex steroid with low or inappropriately normal LH and FSH from a pituitary or hypothalamic cause.
- Spermatogenesis
- Spermatogenesis is the roughly 74-day process by which spermatogonia in the seminiferous tubules become spermatozoa, driven by FSH on Sertoli cells and by very high intratesticular testosterone.
- Ovulation Induction
- Ovulation induction is the pharmacological restoration of ovulation in anovulatory women, distinct from controlled ovarian stimulation, which deliberately recruits many follicles for assisted reproduction.
- Aromatization
- Aromatization is the conversion of androgens to estrogens by the cytochrome P450 enzyme aromatase, turning testosterone into estradiol and androstenedione into estrone.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.